Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.

Breast Cancer Res. 2009;11(3):R27. doi: 10.1186/bcr2257. Epub 2009 May 11.

2.

Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.

McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ.

PLoS One. 2014 Jan 31;9(1):e87032. doi: 10.1371/journal.pone.0087032. eCollection 2014.

3.

Correlation of miRNA expression profiling in surgical pathology materials, with Ki-67, HER2, ER and PR in breast cancer patients.

Sakurai M, Masuda M, Miki Y, Hirakawa H, Suzuki T, Sasano H.

Int J Biol Markers. 2015 May 26;30(2):e190-9. doi: 10.5301/jbm.5000141.

PMID:
25907662
4.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
6.
7.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
8.

Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

J Clin Pathol. 2005 Jun;58(6):611-6.

9.

Hormonal Receptor, Human Epidermal Growth Factor and Its Association with Breast Cancer Tumor Characteristics in Albania.

Pajenga E, Rexha T, Çeliku S, Ugrinska A, Bejtja G.

Cent Eur J Public Health. 2016 Sep;24(3):171-175.

10.

Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Bae SY, Kim S, Lee JH, Lee HC, Lee SK, Kil WH, Kim SW, Lee JE, Nam SJ.

BMC Cancer. 2015 Mar 18;15:138. doi: 10.1186/s12885-015-1121-4.

11.

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

Ann Oncol. 2005 Nov;16(11):1755-61. Epub 2005 Aug 5.

PMID:
16085689
12.
13.

Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer.

Cascione L, Gasparini P, Lovat F, Carasi S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, Shapiro CL, Huebner K.

PLoS One. 2013;8(2):e55910. doi: 10.1371/journal.pone.0055910. Epub 2013 Feb 6.

14.

RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.

Habashy HO, Powe DG, Glaab E, Ball G, Spiteri I, Krasnogor N, Garibaldi JM, Rakha EA, Green AR, Caldas C, Ellis IO.

Breast Cancer Res Treat. 2011 Jul;128(2):315-26. doi: 10.1007/s10549-010-1073-y. Epub 2010 Aug 10.

PMID:
20697807
15.

Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.

Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.

Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055.

PMID:
22489698
16.

Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.

Verma S, Bal A, Joshi K, Arora S, Singh G.

APMIS. 2012 Dec;120(12):1008-19. doi: 10.1111/j.1600-0463.2012.02933.x. Epub 2012 Jul 26.

PMID:
23030684
17.

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.

Yeung C, Hilton J, Clemons M, Mazzarello S, Hutton B, Haggar F, Addison CL, Kuchuk I, Zhu X, Gelmon K, Arnaout A.

Cancer Metastasis Rev. 2016 Sep;35(3):427-37. doi: 10.1007/s10555-016-9631-3. Review.

PMID:
27405651
18.

Association of microRNA-93, 190, 200b and receptor status in core biopsies from stage III breast cancer patients.

Kolacinska A, Morawiec J, Pawlowska Z, Szemraj J, Szymanska B, Malachowska B, Morawiec Z, Morawiec-Sztandera A, Pakula L, Kubiak R, Zawlik I.

DNA Cell Biol. 2014 Sep;33(9):624-9. doi: 10.1089/dna.2014.2419. Epub 2014 May 27.

19.

Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M.

Pathol Oncol Res. 2006;12(2):83-6. Epub 2006 Jun 24.

20.

Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.

Lehmann TP, Korski K, Gryczka R, Ibbs M, Thieleman A, Grodecka-Gazdecka S, Jagodziński PP.

Mol Med Rep. 2015 Sep;12(3):4692-702. doi: 10.3892/mmr.2015.4002. Epub 2015 Jun 26.

PMID:
26130254

Supplemental Content

Support Center